Corient Private Wealth LP Takes Position in Kura Oncology, Inc. $KURA

Key Points

• Corient Private Wealth LP acquired 122,491 shares of Kura Oncology in the second quarter, valued at approximately $1.34 million and representing 0.14% of the company. BlackRock and several other major institutional investors also reported significant KURA positions.
• Insider activity was mixed: CEO Troy Wilson purchased 100,000 shares for about $1.24 million, while insider Mollie Leoni sold 84,929 shares. Company insiders own 7.6% of Kura’s outstanding stock.
• KURA recently traded at $13.25, near its 52-week high, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and an average price target of $25.40. The company exceeded quarterly earnings and revenue expectations but remains unprofitable.

Corient Private Wealth LP bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 122,491 shares of the company's stock, valued at approximately $1,344,000. Corient Private Wealth LP owned 0.14% of Kura Oncology at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Kura Oncology in the second quarter worth approximately $115,286,000. Suvretta Capital Management LLC boosted its position in Kura Oncology by 5.7% during the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company's stock valued at $89,099,000 after buying an additional 459,422 shares during the period. Vanguard Group Inc. boosted its position in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company's stock valued at $57,224,000 after buying an additional 39,105 shares during the period. Armistice Capital LLC grew its holdings in Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company's stock worth $51,285,000 after acquiring an additional 264,000 shares during the last quarter. Finally, State Street Corp increased its position in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company's stock valued at $51,234,000 after acquiring an additional 1,587,959 shares during the period.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider directly owned 182,345 shares of the company's stock, valued at $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Troy Wilson purchased 100,000 shares of Kura Oncology stock in a transaction dated Monday, August 24th. The stock was bought at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the purchase, the chief executive officer directly owned 479,194 shares of the company's stock, valued at approximately $5,937,213.66. This trade represents a 26.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders sold 120,761 shares of company stock valued at $1,283,346. Company insiders own 7.60% of the company's stock.

Kura Oncology Price Performance

KURA stock opened at $13.25 on Friday. The firm has a 50 day moving average price of $11.11 and a 200-day moving average price of $9.81. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $13.90. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -3.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Equities research analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on KURA. Wedbush increased their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Thursday, August 13th. Citigroup reaffirmed a "market outperform" rating on shares of Kura Oncology in a research report on Monday, August 24th. Oppenheimer set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kura Oncology in a research report on Friday, July 17th. Finally, Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research note on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $25.40.

Kura Oncology Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source